此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms (CHIME)

2026年11月12日 更新者:Gaia AG

Investigating the Effectiveness of Calisda, a Digital Health Intervention for Patients With Menopause Symptoms: Randomized Controlled Trial (CHIME Trial)

The goal of this clinical trial is to find out if calisda, a digital health intervention, can help women with menopause symptoms manage their symptoms and improve their quality of life.

The main questions it aims to answer are:

  • Does calisda, together with regular treatment, improve health outcomes after six months better than regular treatment alone?
  • Are the positive effects of calisda already noticeable after three months?

Researchers will compare two groups:

  • Intervention group: Participants use the calisda intervention and continue their usual treatment.
  • Control group: Participants continue with their usual treatment only.

Participants will:

  • Fill out questionnaires online at the start of the study, after 3 months, and after 6 months
  • Continue with their usual treatment (both groups) and use calisda, a digital health intervention, for six months (intervention group only)

研究概览

地位

尚未招聘

干预/治疗

详细说明

This pragmatic, two-arm randomized controlled trial evaluates the effectiveness of calisda, a certified medical device (CE-marked, risk class I), when used alongside regular treatment. The study compares the addition of this digital health intervention to treatment as usual (TAU) against TAU alone. Designed as an interactive online program, calisda incorporates recognized elements of cognitive behavioral therapy (CBT), behavior change, and patient education.

After confirming eligibility, participants are randomly assigned to one of two groups. The intervention group receives immediate access to calisda for six months alongside their usual treatment. The control group continues their regular treatment and is granted access to the intervention after a six-month waiting period.

Data is collected from both groups via online questionnaires at the start of the study, after three months, and after six months. The primary evaluation of effectiveness will be conducted at the six-month follow-up. Data collected at the three-month mark will be utilized to assess early treatment response.

研究类型

介入性

注册 (估计的)

388

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Hamburg、德国
        • GAIA AG

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

40年 至 65年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

女性

描述

Inclusion Criteria:

  • Female biological sex
  • Age 40-65 years
  • Diagnosis of menopause symptoms (ICD-10 code: N95.1) confirmed by a medical document
  • Increased levels of menopause symptoms (MRS-II total score ≥ 14)
  • Reduced menopause-specific quality of life (MENQOL total score ≥ 3)
  • Stable symptom-related treatment (medication, psychotherapy, no treatment, …) for at least 60 days at the time of inclusion
  • Sufficient knowledge of the German language
  • Basic computer skills required for independent use of a digital intervention
  • Consent to participation

Exclusion Criteria:

  • Plans to change symptom-related treatment (medication, psychotherapy, …) in the upcoming 6 months after inclusion
  • Current or history of any malignancy except for basal and squamous cell skin tumors
  • Current HRT use
  • Premature, medically induced menopause (e.g. following bilateral oophorectomy)
  • Known somatic or psychiatric condition that might interfere with successful study participation (e.g. unstable neurologic or psychiatric disorder)
  • Previous use of a digital intervention for menopause symptoms (including calisda) or another digital intervention developed by GAIA.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:calisda

Participants will receive access to the digital health intervention calisda in addition to TAU.

Participants allocated to the intervention group will receive access to calisda in addition to treatment as usual (TAU).

calisda is a digital health intervention designed for women with menopause symptoms, accessible through a web browser. The program focuses on treatment methods derived from cognitive behavioral therapy (CBT), health behavior change, and patient education. Topics addressed by calisda include understanding menopausal changes and symptoms, coping with hot flashes and night sweats, sleep, mood, self-acceptance and self-worth, relationship communication, as well as information on hormone therapy and complementary approaches.

The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their progress. Once registered, the program remains accessible for six months.

无干预:Control group

Participants allocated to the control group will receive access to treatment as usual (TAU).

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
29-item Menopause-Specific Quality of Life Questionnaire (MENQOL; 1-week recall) total score
大体时间:6 months

The MENQOL is a patient-reported outcome measure (PROM) with 29 items. Each item uses a two-stage response format. This questionnaire consists of four domains, with varying item numbers: "vasomotor", "psychosocial", "physical" and "sexual". To obtain the total score, the mean of the domain scores is computed. Both the domain and the total scores range from 1 to 8. Higher total scores indicate greater impairment of quality of life.

6 months

次要结果测量

结果测量
措施说明
大体时间
Hot Flash Related Daily Interference Scale (HFRDIS) total score
大体时间:6 months

The HFRDIS is a 10-item PROM assessing the extent to which hot flashes interfere with daily activities and overall quality of life over the past week. Each item is rated from 0 ("did not interfere") to 10 ("completely interfere"). The total score is the mean of all items and ranges from 0 to 10. Higher total scores indicate greater hot flash interference and thus a worse outcome, whereas lower scores indicate less interference and a better outcome.

6 months
Insomnia Severity Index (ISI) total score
大体时间:6 months

The ISI is a 7-item PROM assessing the nature, severity, and impact of insomnia. Each item is rated on a 5-point scale from 0 to 4. The total score is the sum of all items and ranges from 0 to 28. Higher total scores indicate greater insomnia severity and thus a worse outcome, whereas lower scores indicate less insomnia severity and a better outcome.

6 months
Patient Health Questionnaire (PHQ-9) total score
大体时间:6 months

The PHQ-9 is a 9-item PROM assessing the severity of depressive symptoms. Each item is scored from 0 ("not at all") to 3 ("nearly every day"). The total score is the sum of all items and ranges from 0 to 27. Higher total scores indicate greater depressive symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome.

6 months
Menopause Rating Scale II (MRS-II) total score
大体时间:6 months

The MRS-II is an 11-item PROM assessing the severity of menopause-related symptoms. Each item is rated from 0 ("no complaints") to 4 ("very severe symptoms"). The total score is the sum of all items and ranges from 0 to 44. Higher total scores indicate greater symptom severity and thus a worse outcome, whereas lower scores indicate less severity and a better outcome.

6 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

调查人员

  • 首席研究员:Philipp Klein, Prof. Dr. med.、Universität zu Lübeck, Zentrum für Integrative Psychiatrie ZiP gGmbH

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2027年12月1日

研究完成 (估计的)

2027年12月1日

研究注册日期

首次提交

2026年11月12日

首先提交符合 QC 标准的

2026年11月12日

首次发布 (实际的)

2026年11月18日

研究记录更新

最后更新发布 (实际的)

2026年11月18日

上次提交的符合 QC 标准的更新

2026年11月12日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • calisda RCT 2026

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅